214 related articles for article (PubMed ID: 26377104)
1. Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.
Liu Y; Flynn TJ; Xia M; Wiesenfeld PL; Ferguson MS
Cell Biol Toxicol; 2015 Oct; 31(4-5):221-30. PubMed ID: 26377104
[TBL] [Abstract][Full Text] [Related]
2. Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells.
Liu Y
Methods Mol Biol; 2016; 1473():63-70. PubMed ID: 27518624
[TBL] [Abstract][Full Text] [Related]
3. Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells.
Liu Y
Methods Mol Biol; 2022; 2474():39-46. PubMed ID: 35294754
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Evaluation of Cytochrome P450 3A4 Inhibition and Hepatotoxicity in HepaRG 3-D Spheroids.
Shin DS; Seo H; Yang JY; Joo J; Im SH; Kim SS; Kim SK; Bae MA
Int J Toxicol; 2018; 37(5):393-403. PubMed ID: 29923436
[TBL] [Abstract][Full Text] [Related]
5. A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Trubetskoy O; Marks B; Zielinski T; Yueh MF; Raucy J
AAPS J; 2005 Mar; 7(1):E6-13. PubMed ID: 16146350
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide.
Hoekstra R; Nibourg GA; van der Hoeven TV; Plomer G; Seppen J; Ackermans MT; Camus S; Kulik W; van Gulik TM; Elferink RP; Chamuleau RA
Drug Metab Dispos; 2013 Mar; 41(3):562-7. PubMed ID: 23238784
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
Li AP
Drug Metab Dispos; 2009 Aug; 37(8):1598-603. PubMed ID: 19451401
[TBL] [Abstract][Full Text] [Related]
8. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies.
Jossé R; Aninat C; Glaise D; Dumont J; Fessard V; Morel F; Poul JM; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2008 Jun; 36(6):1111-8. PubMed ID: 18347083
[TBL] [Abstract][Full Text] [Related]
9. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells.
Zahno A; Brecht K; Morand R; Maseneni S; Török M; Lindinger PW; Krähenbühl S
Biochem Pharmacol; 2011 Feb; 81(3):432-41. PubMed ID: 21070748
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jul; 36(7):1444-52. PubMed ID: 18385292
[TBL] [Abstract][Full Text] [Related]
11. Measurement of Cytochrome P450 Enzyme Induction and Inhibition in Human Hepatoma Cells.
Rodrigues RM; De Kock J; Doktorova TY; Rogiers V; Vanhaecke T
Methods Mol Biol; 2015; 1250():279-85. PubMed ID: 26272150
[TBL] [Abstract][Full Text] [Related]
12. A two-dimensional multiwell cell culture method for the production of CYP3A4-expressing hepatocyte-like cells from HepaRG cells.
Ooeda K; Kubiura-Ichimaru M; Tsuji S; Okuyama S; Yamashita M; Mine A; Kawamura F; Ueyama T; Tada M
Pharmacol Res Perspect; 2020 Oct; 8(5):e00652. PubMed ID: 32955797
[TBL] [Abstract][Full Text] [Related]
13. Dual-color fluorescence imaging to monitor CYP3A4 and CYP3A7 expression in human hepatic carcinoma HepG2 and HepaRG cells.
Tsuji S; Kawamura F; Kubiura M; Hayashi A; Ohbayashi T; Kazuki Y; Chesné C; Oshimura M; Tada M
PLoS One; 2014; 9(8):e104123. PubMed ID: 25101946
[TBL] [Abstract][Full Text] [Related]
14. CYP3A4 inhibition by
Liu Y; Flynn TJ
Toxicol Rep; 2015; 2():530-534. PubMed ID: 28962388
[No Abstract] [Full Text] [Related]
15. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Hardy KD; Wahlin MD; Papageorgiou I; Unadkat JD; Rettie AE; Nelson SD
Drug Metab Dispos; 2014 Jan; 42(1):162-71. PubMed ID: 24191259
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
[TBL] [Abstract][Full Text] [Related]
18. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.
Gerets HH; Tilmant K; Gerin B; Chanteux H; Depelchin BO; Dhalluin S; Atienzar FA
Cell Biol Toxicol; 2012 Apr; 28(2):69-87. PubMed ID: 22258563
[TBL] [Abstract][Full Text] [Related]
19. 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies.
Mueller D; Krämer L; Hoffmann E; Klein S; Noor F
Toxicol In Vitro; 2014 Feb; 28(1):104-12. PubMed ID: 23850736
[TBL] [Abstract][Full Text] [Related]
20. Activation of the aryl hydrocarbon receptor decreases rifampicin-induced CYP3A4 expression in primary human hepatocytes and HepaRG.
Rasmussen MK; Daujat-Chavanieu M; Gerbal-Chaloin S
Toxicol Lett; 2017 Aug; 277():1-8. PubMed ID: 28571685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
